Israel, Victoria biotech fund kicks off

The winning projects - which focus on medical equipment, pharmaceuticals and information technologies - receive grants of up to half of the total investment in the project, but not more than $500,000

By DANIEL KENNEMER
August 8, 2006 09:05

 
X

Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later Don't show it again

Vistech - a fund supporting biotech projects led jointly by companies in Israel and the Australian state of Victoria - has awarded grants to four of six projects that answered its initial February call for submissions, the Industry, Trade and Labor Ministry said Monday. The winning projects - which focus on medical equipment, pharmaceuticals and information technologies - receive grants of up to half of the total investment in the project, but not more than $500,000. A second group of candidate projects are currently being submitted, the ministry said, adding that the fund helps Israeli companies find partners in Victoria.

Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection

By GLOBES, NIV ELIS